Branded Generic vs. Authorized Generic: Which Strategy Offers Higher ROI at the Patent Cliff
When a blockbuster drug’s patent expires, the originator company faces a choice that will define its revenue trajectory for the […]
When a blockbuster drug’s patent expires, the originator company faces a choice that will define its revenue trajectory for the […]
Two federal statutes govern most of what happens when a pharmaceutical patent expires in the United States. One dates to
Every year, billions of dollars in branded drug revenue evaporate on a single day: the day a generic or branded
AbbVie held Humira’s U.S. market alone for twenty years. Not because it held one brilliant patent, but because it built
Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a
Branded Generic ROI: The Cold Math Behind a Controversial Strategy Read Post »
The difference between first place and second place in the generic drug market is not measured in prestige. It is
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit Read Post »
AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan
Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue
The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed
Sign in or create a free account to read this DrugPatentWatch article